Understanding the cellular function of TRPV2 channel through generation of specific monoclonal antibodies

Matthew R Cohen1, Kevin W Huynh2, Daniel Cawley3

  • 1Department of Physiology & Biophysics, School of Medicine, Case Western Reserve University, Cleveland, Ohio, United States of America ; Department of Pharmacology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, United States of America.

Plos One
|January 7, 2014
PubMed

Insights

New monoclonal antibodies for Transient Receptor Potential Vanilloid 2 (TRPV2) were developed and validated. These tools show insulin-like growth factor 1 (IGF-1) does not affect TRPV2 surface expression, resolving prior scientific debate.

Area of Science:

  • Molecular biology
  • Cell biology
  • Immunology

Background:

  • Transient Receptor Potential Vanilloid 2 (TRPV2) is a calcium-permeable channel implicated in cellular processes.
  • Previous studies on TRPV2 trafficking and function are hindered by a lack of validated antibodies.
  • Conflicting results exist regarding growth factor signaling, like insulin-like growth factor 1 (IGF-1), and TRPV2 surface expression.

Purpose of the Study:

  • To develop and characterize novel monoclonal antibodies for accurate detection of endogenous TRPV2.
  • To investigate the effect of IGF-1 on TRPV2 trafficking and plasma membrane expression using validated antibodies.

Main Methods:

  • Generation of monoclonal antibodies against full-length TRPV2.
  • Validation of newly developed antibodies via Western blot, immunoprecipitation, and immunocytochemistry.
  • Comparison of novel antibodies with commercially available polyclonal TRPV2 antibodies.
  • Assessment of IGF-1 effects on TRPV2 surface expression in various cell systems.

Main Results:

  • Newly generated monoclonal antibodies successfully detected endogenous TRPV2.
  • Commercially available polyclonal TRPV2 antibodies failed to recognize endogenous TRPV2.
  • IGF-1 demonstrated minimal to no impact on TRPV2 trafficking and plasma membrane expression.

Conclusions:

  • Validated monoclonal antibodies are essential for reliable TRPV2 research.
  • IGF-1 does not significantly alter TRPV2 surface expression, clarifying previous controversies.
  • This antibody generation strategy can be applied to other TRP channels.